NEW YORK (GenomeWeb) – Asuragen said this week that it has appointed Matthew McManus as CEO and president.

McManus was most recently CEO and president of PrimeraDx, and MDx platform developer recently acquired by Qiagen. Prior to this, he was head of Cleveland Clinic Laboratories and chief operating officer of the Pathology and Laboratory Medicine Institute at the Cleveland Clinic. He holds an MD and PhD from the University of Pennsylvania School of Medicine and an MBA from Boston College.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.